ASCO GI 2023 Conference Coverage


 

ASCO GI 2023 Debate: For a Fit Patient With Unresectable Metastatic RAS Wild-Type Sigmoid Colon Adenocarcinoma, 1L EGFR Antibody Is an Essential Treatment - PRO

149 views
February 6, 2023
Comments 0
Login to view comments. Click here to Login